Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193805-25-001316
Filing Date
2025-09-19
Accepted
2025-09-19 12:23:56
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10512
2 e664843_ex99-a.htm EX-99.(A) 3638
3 e664843_ex99-b.htm EX-99.(B) 985
  Complete submission text file 0001193805-25-001316.txt   16622
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Subject) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-44055 | Film No.: 251325738
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 780 THIRD AVENUE 37TH FLOOR NEW YORK NY 10017
Business Address
Flynn James E (Filed by) CIK: 0001352546 (see all company filings)

Type: SCHEDULE 13G